Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer

Study of Larotinib in Unresectable Advanced or Recurrent Oesophageal Cancer is a phase 3 interventional study registered as NCT04415853, led by Sunshine Lake Pharma, and recruiting on the registry. Official title: Lerotinib Versus Investigator's Choice Single-agent Chemotherapy in Patients With Locally Advanced/Metastatic Oesophageal Squamous Cell Carcinoma and EGFR Overexpression That Progressed After Second-line Therapy:Phase 3 Study. Planned enrolment is 416 participants (estimated). The study started in 2021-01-21 and primary completion is expected in 2026-08. No results have been posted on ClinicalTrials.gov.